MedPath

An open label study to evaluate the efficacy, safety and tolerability of RWJ333369 as adjunctive therapy in subjects with partial onset seizure

Conditions
Partial Onset Epilepsy Seizures
Registration Number
EUCTR2007-001801-99-HU
Lead Sponsor
Janssen-Cilag International N.V.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
510
Inclusion Criteria

For the double blind trial 3002:
1. Male or female aged 16 years or older, inclusive. 2. Weight of at least 40 kg. 3. Established diagnosis of partial epilepsy for at least 1 year, using ILAE criteria. 4. History of inadequate response to at least 1 AED. 5. Current treatment with at least 1 and no more than 2 AED's. 6. Have had at least 3 simple partial motor, complex partial, or secondarily generalized seizures per month, and no seizure-free interval for more than 3 weeks. 6. Post-menopausal females, or those using acceptable method of birth control.
Inclusion criteria for study 3004:
subject must complete the 12-week double-blind treatment phase of study 333369-EPY-3002
subject must have signed a separate informed consent form for open-label extension study (333369-EPY-3004)
Are the trial subjects under 18? yes
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

1. History of status epilepticus within 6 months before study entry. 2. Generalized epileptic syndrome or having only absence, atonic/tonic, or simple partial sensory or other simple partial type seizures. 3. Lennox-Gastaut Syndrome 4. Current serious or medically unstable systemic diseases. 5. Current major depression, or history of suicide within last 2 years. 6. History of drug or alcohol abuse. 7. Positive for hepatitis B or C, or HIV/AIDS. 8. History of drug-induced liver injury, or diagnosis of any form of chronic liver disease.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: The primary objective of this open label study is to determine the long-term safety and tolerability of RWJ-333369 as adjunctive treatment of partial onset seizures. Safety evaluation will include worsening of seizures, including rates of status epilepticus.;Secondary Objective: The secondary objective of this study to determine health-related status as measured by the Quality of Life in Epilepsy-31 problems (QOLIE-31-P) outcomes scale.;Primary end point(s): The primary objective of this study is to determine the long-term safety and tolerability of RWJ-333369 as adjunctive treatment of partial onset seizure. Safety evaluation will include worsening of seizures, including rates of status epilepticus.<br>Subject diaries will be the source of all seizure data.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath